Serum levels of vascular endothelial growth factor and cancer antigen 125 are related to the prognosis of adenomyosis patients after interventional therapy.
article
OA: green
CC0
⤵ 9 in-corpus citations
AI-generated summary
Serum levels of vascular endothelial growth factor and cancer antigen 125 were elevated in adenomyosis patients and correlated with poorer prognosis after interventional therapy.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
AIMS: This study is to investigate the expression levels of vascular endothelial growth factor (VEGF) and cancer antigen 125 (CA125) in serum of adenomyosis patients before and after interventional therapy. The role of serum levels of VEGF and CA125 for the prognosis of adenomyosis is further studied. METHODS: A total of 80 adenomyosis patients treated with interventional therapy and 40 healthy individuals were enrolled in this study. Enzyme-linked immunosorbent assay was performed to detect the expression levels of VEGF and CA125. Receiver operating characteristic analysis was used to determine the treatment effect on adenomyosis. Kaplan-Meier analysis was used to analysis the progression-free survival curve for prognosis of adenomyosis. RESULTS: The expression levels of VEGF and CA125 in serum of patients with adenomyosis was increased when compared with those of healthy individuals before interventional therapy (P < 0.05). Levels of hemoglobin in adenomyosis patients after surgery was increased compared with those before surgery (P < 0.05). The blood volume of menstruation, pain intensity, and volume of uterus in adenomyosis patients after surgery was significantly decreased when compared with those before surgery (P < 0.01). The survival rate of adenomyosis patients with high VEGF and CA125 levels was decreased. Serum levels of VEGF and CA125 had a high sensitivity and specificity for the prognosis of adenomyosis. CONCLUSIONS: The serum expression levels of VEGF and CA125 are related to the development of adenomyosis. VEGF and CA125 serum levels can be used for predicting the prognosis of adenomyosis.
My notes (saved in your browser only)
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (13)
- Multitasking Human Endometrium via openalex
- [Serum and peritoneal fluid CA-125 concentration in women with endometriosis]. via openalex
- [Study on the expression of vascular endothelial growth factor in patients with adenomyosis of the uterus]. via openalex
- W2026766164 via openalex
- W2032479841 via openalex
- W2054264645 via openalex
- W2006561283 via openalex
- W2093673524 via openalex
- W2105620133 via openalex
- W2138453840 via openalex
- W2169576035 via openalex
- W1988087076 via openalex
- W1900386759 via openalex
Cited by (9)
- Role of Vascular Endothelial Cell Growth Factor on Pathophysiology of Uterine Adenomyosis 2022
- The Pathogenesis of Adenomyosis 2021
- Prediction of outcomes of hysteroresectoscopic endometrial destruction in patients with endometrial hyperplasia without atypia 2020
- <p>Comparisons of the efficacy and recurrence of adenomyomectomy for severe uterine diffuse adenomyosis via laparotomy versus laparoscopy: a long-term result in a single institution</p> 2019
- Combined therapeutic effects of HIFU, GnRH-a and LNG-IUS for the treatment of severe adenomyosis 2019
- IMBALANCE IN CYTOKINE NETWORK/REGULATORY TRANSPORT PROTEIN SYSTEM IN VARIOUS TYPES OF INFERTILITY DURING IN VITRO FERTILIZATION PROGRAMS 2018
- Pathogenesis of adenomyosis: an update on molecular mechanisms 2017
- Ali Farid’s Updated Innovation in Women Reproduction 2016
- Proangiogenic features in chronic pelvic pain caused by adenomyosis 2016
Source provenance
- europepmc
- last seen: 2026-08-09T06:10:49.860119+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:17:39.907309+00:00
License: CC0
· commercial use OK